1987
DOI: 10.1001/archderm.123.1.55
|View full text |Cite
|
Sign up to set email alerts
|

Etretin therapy for severe psoriasis. Evaluation of initial clinical responses

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
7
0

Year Published

1987
1987
2011
2011

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 0 publications
1
7
0
Order By: Relevance
“…The results of the present systematic review suggest that the starting dose of acitretin should not exceed 25 mg/day, with further progressive, stepwise dosage escalation in order to limit the incidence and severity of adverse events 6 . The optimal acitretin dose ranges between 25 and 50 mg/day 16,18,21 . Higher dosage was associated with significantly increased incidence of adverse events possibly leading to treatment withdrawal 18 .…”
Section: Discussionmentioning
confidence: 86%
See 3 more Smart Citations
“…The results of the present systematic review suggest that the starting dose of acitretin should not exceed 25 mg/day, with further progressive, stepwise dosage escalation in order to limit the incidence and severity of adverse events 6 . The optimal acitretin dose ranges between 25 and 50 mg/day 16,18,21 . Higher dosage was associated with significantly increased incidence of adverse events possibly leading to treatment withdrawal 18 .…”
Section: Discussionmentioning
confidence: 86%
“…Among an initial selection of 1348 references, we finally included 44 references, reporting data from 37 RCTs and eight cohort studies in the systematic review 6–49 . The detailed flowchart describing both selection process and reasons for exclusion is illustrated in Fig.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Acitretin is the free acid and principal metabolite of etretinate. Initial studies in which acitretin was used for psoriasis-as monotherapy in the United States 6,7 and in combination with conventional therapies in Europe 8 ' 9 -indicated that it may be similar to etretinate in efficacy and toxicity. The advantage of this new retinoid over etretinate is that it has a half-life of 50 hours; therefore, acitretin cannot be detected in serum 3 weeks after discontinuation of treatment.…”
mentioning
confidence: 99%